



Mike Braun, Governor  
State of Indiana

***Indiana Family and Social Services Administration***  
***Office of Medicaid Policy and Planning***

402 W. WASHINGTON ST., ROOM W374, MS07  
INDIANAPOLIS, IN 46204

**MEETING AGENDA AND PUBLIC NOTIFICATION**

**Meeting:** Indiana Medicaid DUR Board

**Date:** May 16, 2025

**Time:** 10:00 a.m. EST

**Location:** Hybrid Format

Indiana State Government Center South  
Conference Room B

Virtual Meeting Information Below

1. Call to Order, Remarks of the Chair
2. Opening Comments: OMPP
3. Approval of Minutes
4. Update: OptumRx
  - Call Center Prior Authorization Statistics
  - MHQAC Utilization Edits
  - Preferred Drug List Review/Therapeutics Committee Recommendations from the Committee's February 7, 2025, Meetings to Review the SUPDL – reference IC 12-15-28(a)
  - Preferred Drug List Review/Therapeutics Committee Recommendations from the Committee's May 2, 2025, Meetings to Review the PDL – reference IC 12-15-28(a)
  - CMS DUR Annual Report Review
  - Initiating Medication for Opioid Use Disorder (MOUD) Health Equity Initiative Retrospective Drug Utilization Review (Retro-DUR) Follow-Up Analysis
  - Statin Therapy in Diabetics Retro-DUR Follow-Up Analysis
  - Retro-DUR proposal
    - i. DUR Board Newsletter topics proposal



5. Update: Managed Care Pharmacy

- Anthem – Aimee Burger
- CareSource – Beth McCarty
- Humana – Bill Porch
- Managed Health Services – Farhan Hasan
- MDwise – Wendi Powell
- United Healthcare – Monica Blankenship

6. MME Reduction Project Update

7. New Drugs

- Agents for the Treatment of Cystic Fibrosis
  - i. Alyftrek (vanzacaftor/tezacaftor/deutivacaftor)
- Complement Inhibitor Agents PA
  - i. Bkemb (eculizumab-aeeb)
  - ii. Epysqli (eculizumab-aagh)
- Non-SUPDL Agents PA and ST
  - i. Abrysvo (respiratory syncytial virus vaccine)
  - ii. Inzirgo (hydrochlorothiazide)
  - iii. Journavx (suzetrigine)
- Transthyretin Stabilizer Agents
  - i. Amvuttra (vutrisiran)
- Vaccines
  - i. Abrysvo (respiratory syncytial virus vaccine)
  - ii. Arexvy (respiratory syncytial virus vaccine)
  - iii. Penmenvy (meningococcal vaccine)
  - iv. Vimkunya (chikungunya vaccine)
- Zepbound (tirzepatide)

8. Liaison with Other Boards

9. Old Business

10. New Business

- Agents for MASH and MASLD
  - i. Rezdiffra (resmetirom)
- Agents for the Treatment of Cystic Fibrosis
  - i. Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
- Allergy-Specific Immunotherapy PA Criteria
  - i. Odactra (dust mite allergen extract)
- Complement Inhibitor Agents
  - i. Fabhalta (iptacopan)

- ii. Soliris (eculizumab)
- DPP-4 Inhibitors and Combination Agents
- GLP-1 Receptor Agonists and Combinations
- Niemann-Pick Disease Agents
  - i. Aqneursa (levacetylleucine)
  - ii. Miplyffa (arimoclomol)
- Opioid Use Disorder Treatments
  - i. Brixadi (buprenorphine)
  - ii. Sublocade (buprenorphine)
- Transthyretin Stabilizer Agents
  - i. Attruby (acoramidis)
- Additional items at the discretion of the Board

11. Public Comment

12. Adjourn

---

**Microsoft Teams** [Need help?](#)

[Join the meeting now](#)

Meeting ID: 262 218 775 031

Passcode: 5uddyd

---

**Dial in by phone**

[+1 952-222-7450,,491748694#](#) United States, Minneapolis

[Find a local number](#)

Phone conference ID: 491 748 694#

**Join on a video conferencing device**

Tenant key: teams@optum.onpexip.com

Video ID: 114 921 788 49

[More info](#)

For organizers: [Meeting options](#) | [Reset dial-in PIN](#)

[Org help](#)

---

---